Kamada Ltd. Submits U.S. Biologics License Application for the First Liquid, Ready to Use AAT for the Treatment of Alpha-1 Antitrypsin Deficiency

ClinicaSpace Login

Enter your ClinicaSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

Clinical Research
News & Careers

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
FREE Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Date
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Today's Hot Jobs
Most Recent Jobs
Search Jobs
Post Resume
Career Resources
For Employers

COMMUNITY
Login
Become a Member
FAQ

PROFILES
Company Profiles

INDUSTRY EVENTS
Clinical

RESOURCES
Real Estate
New Business Opportunities

News | News By Subject | News By Date | Search News

Email

Kamada Ltd. Submits U.S. Biologics License Application for the First Liquid, Ready to Use AAT for the Treatment of Alpha-1 Antitrypsin Deficiency
6/2/2009

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA) – a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that it has submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for its lead clinical candidate, intravenous alpha-1 antitrypsin (“AAT-IV”), for the treatment of Alpha-1 Antitrypsin Deficiency.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Kamada Ltd.

• Clinical - BLA/NDA/ANDA